Startseite>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

Katalog-Nr.GC61257

S-(1-Hydroxy-2-methylpropan-2-yl)methansulfonothioat ist ein durch Glutathion spaltbarer ADC-Linker, der fÜr die AntikÖrper-Wirkstoff-Konjugate (ADCs) verwendet wird und sich auf die Alkylketten-Zusammensetzung bezieht. S-(1-Hydroxy-2-methylpropan-2-yl)methansulfonothioat sind die Linker-Teile der MolekÜle, die fÜr mAb-Anheftungszwecke verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate Chemische Struktur

Cas No.: 2127875-65-2

Größe Preis Lagerbestand Menge
50mg
445,00 $
Auf Lager
100mg
630,00 $
Auf Lager
250mg
908,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition. S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is the linker portions of the molecules employed for mAb attachment purposes[1].

[1]. Pillow TH, et al. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity. ChemMedChem. 2019 Oct 31.

Bewertungen

Review for S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.